Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully h ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Dupilumab is undergoing Priority Review by the FDA as an add-on maintenance therapy for adults with uncontrolled COPD and type 2 inflammation, with a target action date of June 27, 2024, according ...

Dupilumab Improves Quality of Life for COPD Patients — There remains an unmet need for effective COPD therapies, expert says by Katherine Kahn , Staff Writer, MedPage Today October 10, 2024 ...

For these patients, dupilumab is a welcome addition to the COPD-treatment armamentarium, he said. The approval was based on data from a pair of phase 3 studies known as BOREAS and NOTUS.

SAN FRANCISCO — The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings ...

Dupixent (dupilumab) late-breaking phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine. May 21, 2023. Accessed September 26, 2024.

MONDAY, Oct. 7, 2024 (HealthDay News) -- Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according ...

Dupixent®, or dupilumab, was the first biologic medicine approved for COPD in the U.S., and targets IL-4 and IL-13 signaling, which are two of the key immune molecules involved in a type 2 ...

Surya Bhatt, M.D., MSPH Surya Bhatt, M.D., MSPH, professor of medicine in the Division of Pulmonary, Allergy, & Critical Care Medicine, is the latest winner of the Heersink School of Medicine's ...

B OSTON -- Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in quality of life with dupilumab (Dupixent) versus placebo, according to a ...